Trial document

This study has been imported from without additional data checks.
drksid header


Trial Description

start of 1:1-Block title


A Phase II, Open-label, Study in Subjects With BRAF V600E-Mutated Rare Cancers With Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

This is a Phase II, open-label, non-randomized, multi-center study of oral Dabrafenib in
combination with oral Trametinib in subjects with rare cancers including anaplastic thyroid
cancer, biliary tract cancer, gastrointestinal stromal tumor, non-seminomatous germ cell
tumor/non-geminomatous germ cell tumor, hairy cell leukemia, World Health Organization (WHO)
Grade 1 or 2 glioma, WHO Grade 3 or 4 (high-grade) glioma, multiple myeloma, and
adenocarcinoma of the small intestine, with BRAF V600E positive-mutations. This study is
designed to determine the overall response rate (ORR) of oral Dabrafenib in combination with
oral Trametinib in subjects with rare BRAF V600E mutated cancers. Subjects will need to have
a fresh or frozen tumor tissue sample provided to confirm the BRAF V600E mutation status.
Only subjects with histologically confirmed advanced disease and no available standard
treatment options will be eligible for enrollment. Subjects will undergo screening
assessments within 14 days (up to 35 days for ophthalmology exam, echocardiogram or disease
assessments) prior to the start of treatment to determine their eligibility for enrollment
in the study.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language


end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00007132
  •   2014/12/15
  •   2013/12/05
  •   no
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   NCT02034110  (
  •   117019  (GlaxoSmithKline)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Cancer
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: Dabrafenib
  •   Drug: Trametinib
end of 1:N-Block interventions
start of 1:1-Block design


  •   Interventional
  •   [---]*
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Treatment
  •   Single (group)
  •   II
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Overall response rate (ORR); time frame: Possibly up to Week 208; To determine the ORR as measured radiographically via Response Evaluation Criteria in Solid tumors (RECIST) version 1.1 for solid tumor histologies or established response criteria for specific hematologic malignancies.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Duration of response; time frame: From the time of first documented evidence of CR or PR until the first documented sign of disease progression or death (approximately up to Week 208); Duration of response is defined as the subset of subjects who show a confirmed clinical response (CR) or partial response (PR), the time from first documented evidence of CR or PR until the first documented sign of disease progression or death.
- Investigator-assessed Progression-free survival (PFS); time frame: Possibly up to Week 208; PFS is defined as the time from the date of enrollment to the earliest date of progression or death.
- Overall Survival (OS); time frame: Until death or lost to follow-up (approximately up to Week 208); OS is defined as the time from the date of enrollment to the date of death due to any cause.
- Change from baseline in physical examination findings; time frame: Possibly up to Week 208; Examination will include assessments of the head and neck, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes, extremities and genitalia. Height (measured only at Screening) and weight will be measured and recorded. Complete physical examinations will also include thorough rectal and genitourinary (pelvic) examinations to assess secondary malignancies.
- Change from baseline in vital signs; time frame: Possibly up to Week 208; Vital sign measurements will include systolic and diastolic blood pressure, temperature, pulse rate and respiratory rate
- Number of subjects with Adverse events (AEs); time frame: Possibly up to Week 208; AE is any untoward medical occurrence in a subject or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
- Change from baseline in laboratory values; time frame: Possibly up to Week 208; Laboratory assessments include haematology, clinical chemistry, urinalysis, coagulation and histology-specific tests
- Change from baseline in cardiac assessments; time frame: Possibly up to Week 208; Cardiac assessments include Electrocardiogram (ECG) and Echocardiograms (ECHOs)

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   United States
  •   Austria
  •   Belgium
  •   Denmark
  •   France
  •   Germany
  •   Italy
  •   Korea, Republic of
  •   Norway
  •   Sweden
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   [---]*
  •   2014/03/31
  •   135
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

- Signed, written informed consent.

- Sex: male or female.

- Age: >=18 years of age at the time of providing informed consent.

- Eastern Cooperative Oncology Group (ECOG) performance status: 0, 1 or 2.

- BRAF V600E mutation-positive tumor: Local testing - Local BRAF mutation test results
obtained by a Clinical Laboratory Improvement Amendments (CLIA) approved local
laboratory may be used to permit enrollment of subjects with positive results. Local
BRAF mutation test results will be subject to central verification; Central testing -
Local BRAF mutation test results will be confirmed by central testing in a CLIA
approved, designated central reference laboratory by the THxID BRAF assay or an
alternate GSK designated assay. NOTE: For central testing, Formalin-fixed
paraffin-embedded (FFPE) core bone marrow (BM) biopsies are not acceptable from
subjects in the Multiple myeloma (MM) cohort.

- Able to swallow and retain orally administered medication. NOTE: Subject should not
have any clinically significant gastrointestinal (GI) abnormalities that may alter
absorption such as malabsorption syndrome or major resection of the stomach or
bowels. For example, subjects should have no more than 50% of the large intestine
removed and no sign of malabsorption (i.e., diarrhea).NOTE: If clarification is
needed as to whether a condition will significantly affect the absorption of study
treatments, contact the GSK Medical Monitor.

- Female Subjects of Childbearing Potential: Subjects must have a negative serum
pregnancy test within 7 days prior to the first dose of study treatment and agrees to
use effective contraception, throughout the treatment period and for 4 months after
the last dose of study treatment.

- French subjects: In France, a subject will be eligible for inclusion in this study
only if either affiliated to or a beneficiary of a social security category.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- Prior treatment with: BRAF and/or MEK inhibitor(s); anti-cancer therapy (e.g.,
chemotherapy with delayed toxicity, immunotherapy, biologic therapy or
chemoradiation) within 21 days (or within 42 days if prior nitrosourea or mitomycin C
containing therapy) prior to enrollment and/or daily or weekly chemotherapy without
the potential for delayed toxicity within 14 days prior to enrolment; Investigational
drug(s) within 30 days or 5 half-lives, whichever is longer, prior to enrollment

- Previous major surgery within 21 days prior to enrollment.

- Prior extensive radiotherapy treatment within 21 days prior to enrolment. NOTE:
Limited radiotherapy for palliative care is permitted within 14 days prior to
enrollment as long as any radiation-related toxicity has resolved prior to

- Prior solid organ transplantation or allogenic stem cell transplantation (ASCT).
NOTE: Previous autologous bone marrow transplant (ABMT) or autologous peripheral
blood stem cell transplant (PBSCT) is permitted.

- History of: Interstitial lung disease or pneumonitis; Another malignancy. NOTE:
Subjects with another malignancy are eligible if: (a) disease-free for 3 years, (b)
had a history of completely resected non-melanoma skin cancer, and/or (c) have a
indolent second malignancy(ies) defined as a slow growing second/concurrent
malignancy which is characterized by slow growth, a high initial response rate and a
relapsing , progressive disease course. For example, a previously untreated low grade
and select intermediate-grade lymphoid malignancy would be allowed as per the
available body of evidence. There are no available clinical alternatives to the
proposed population. Consult a GSK Medical Monitor if unsure whether second
malignancies meet requirements specified above.

- Presence of: cerebral metastases (except for subjects in the WHO Grade 1 or 2 Glioma
or WHO Grade 3 or 4 Glioma histology cohorts). NOTE: Subjects with brain metastases
may be included if: All known lesions have been previously treated with surgery or
stereotactic radiosurgery, and Any remaining cerebral lesion(s) are asymptomatic and
confirmed stable disease (i.e., no increase in lesion size) for >=90 days prior to
enrollment as documented by two consecutive magnetic resonance imaging (MRI) or
computed tomography (CT) scans with contrast, and No treatment with corticosteroids
or enzyme-inducing anticonvulsants required for >=30 days prior to enrolment.
Approval received from GSK Medical Monitor.

- Presence of symptomatic or untreated leptomeningeal or spinal cord compression. NOTE:
Subjects who have been previously treated for these conditions and have stable
central nervous system (CNS) disease (documented by consecutive imaging studies) for
>60 days, are asymptomatic and currently not taking corticosteroids, or have been on
a stable dose of corticosteroids for at least 30 days prior to enrollment, are

- Presence of pre-existing >= Grade 2 peripheral neuropathy.

- Presence of unresolved treatment-related toxicity of >= Grade 2 (except alopecia) or
toxicities listed in the general and histology-specific adequate organ function
tables at the time of enrolment.

- Presence of any serious and/or unstable pre-existing medical disorder (aside from
malignancy exception above), psychiatric disorder, or other conditions that could
interfere with subject's safety, obtaining informed consent or compliance to the
study procedures.

- History or current evidence/risk of retinal vein occlusion (RVO) or central serous
retinopathy (CSR): History of RVO or CSR, or predisposing factors to RVO or CSR
(e.g., uncontrolled glaucoma or ocular hypertension, uncontrolled systemic disease
such as hypertension or diabetes mellitus, or history of hyperviscosity or
hypercoagulability syndromes); Visible retinal pathology as assessed by ophthalmic
examination that is considered a risk factor for RVO or CSR such as evidence of new
optic disc cupping, evidence of new visual field defects and intraocular pressure >21

- History or evidence of cardiovascular risk including any of the following: Acute
coronary syndromes (including myocardial infarction and unstable angina), coronary
angioplasty, or stenting within 6 months prior to enrolment; Clinically significant
uncontrolled arrhythmias NOTE: Subjects with controlled atrial fibrillation for >30
days prior to enrollment are eligible; Class II or higher congestive heart failure as
defined by the New York Heart Association (NYHA) criteria; Left ventricular ejection
fraction (LVEF) below the institutional lower limit of normal (LLN). NOTE: If a LLN
does not exist at an institution, then use LVEF <50%.; Corrected QT (QTc) interval
for heart rate using Bazett-corrected QT interval (QTcB) >=480 millisecond (msec);
Intracardiac defibrillator and/or permanent pacemaker; Treatment-refractory
hypertension defined as a blood pressure (BP) >140/90 millimeters of mercury (mmHg)
which may not be controlled by anti-hypertensive medication(s) and/or lifestyle
modifications; Known cardiac metastases.

- Current use of prohibited medication(s) or requirement of prohibited medications
during study. NOTE: Use of anticoagulants such as warfarin is permitted; however,
international normalization ratio (INR) must be monitored according with local
institutional practice.

- Positive for: Hepatitis B surface antigen or Hepatitis C antibody. NOTE: Subjects
with laboratory evidence of cleared hepatitis B virus (HBV) and hepatitis C virus
(HCV) infection will be permitted. NOTE: False positive subjects may be cleared for
enrollment based on RNA-based assays; Human immunodeficiency virus (HIV); testing not

- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
chemically related to study treatment, or excipients, or to dimethyl sulfoxide and/or
sulfonamides (structural component of dabrafenib).

- Female subjects: Pregnant, lactating or actively breastfeeding.

- Subjects enrolled in France: The French subject has participated in any study using
an investigational product (IP) within 30 days prior to enrollment in this study.

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


  • start of 1:1-Block address primary-sponsor
    • GlaxoSmithKline
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • GlaxoSmithKline
    • GSK Clinical Trials 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • US GSK Clinical Trials Call Center 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
The parameters in and DRKS are not identical. Therefore the data import from required adjustments. For full details please see the DRKS FAQs .
  •   46
  •   2014/10/27
* This entry means the parameter is not applicable or has not been set.